teriflunomide

GPTKB entity

Statements (56)
Predicate Object
gptkbp:instance_of gptkb:drug
gptkbp:bfsLayer 5
gptkbp:bfsParent gptkb:Tavium
gptkb:Aubagio
gptkbp:activities dihydroorotate dehydrogenase inhibitor
gptkbp:approves gptkb:legislation
gptkb:2012
gptkb:United_States
gptkbp:availability prescription only
gptkbp:brand gptkb:Aubagio
gptkbp:clinical_trial Phase III
long-term treatment
gptkbp:contraindication pregnancy
severe renal impairment
severe liver impairment
gptkbp:developed_by gptkb:Sanofi
gptkbp:discovered_by Dr. Robert J. Fox
gptkbp:dosage_form 7 mg or 14 mg daily
gptkbp:excretion urine
gptkbp:formulation gptkb:tablet
https://www.w3.org/2000/01/rdf-schema#label teriflunomide
gptkbp:indication gptkb:relapsing_forms_of_multiple_sclerosis
gptkbp:ingredients C12 H9 N3 O2
gptkbp:interacts_with gptkb:warfarin
other immunosuppressants
gptkbp:is_atype_of L04 A A18
gptkbp:is_monitored_by blood pressure
liver function tests
complete blood count
gptkbp:is_used_for gptkb:psychologist
gptkbp:lifespan 18 hours
gptkbp:manager oral
gptkbp:marketed_as gptkb:Aubagio
gptkbp:metabolism liver
gptkbp:pharmacokinetics highly protein-bound
immunomodulatory effects
gptkbp:population adults
children over 10 years old
gptkbp:price varies by region
gptkbp:research_areas clinical trials
neurology
autoimmune diseases
pharmacology
gptkbp:safety_features generally well tolerated
gptkbp:side_effect fatigue
headache
nausea
hypertension
diarrhea
liver toxicity
infections
peripheral neuropathy
skin rash
hair loss
gptkbp:type_of 162401-32-3
gptkbp:year_created gptkb:2000